a7-Nicotinic acetylcholine receptor (a7nAChR) agonists confer protection against a wide variety of cytotoxic insults and suppress oxidative stress and apoptosis in various cell systems, including hepatocytes. We recently demonstrated that nicotine, when combined with a high-fat diet (HFD), triggers oxidative stress, activates hepatocyte apoptosis, and exacerbates HFD-induced hepatic steatosis in male mice. This study evaluates whether PNU-282987 (PNU), a specific a7nAChR agonist, is effective in preventing nicotine plus HFD-induced hepatic steatosis. Adult C57BL6 male mice were fed a normal chow diet or HFD with 60% of calories derived from fat and received twice-daily intraperitoneal injections of 0.75 mg/kg body weight (BW) of nicotine, PNU (0.26 mg/kg BW), PNU plus nicotine, or saline for 10 weeks. PNU treatment was effective in attenuating nicotine plus HFD-induced increase in hepatic triglyceride levels, hepatocyte apoptosis, and hepatic steatosis. The preventive effects of PNU on nicotine plus HFD-induced hepatic steatosis were mediated by suppression of oxidative stress and activation of adenosine 5 0 -monophosphate-activated protein kinase (AMPK) together with inhibition of its downstream target sterol regulatory element binding protein 1c (SREBP1c), fatty acid synthase (FAS), and acetyl-coenzyme A-carboxylase (ACC). We conclude that the a7nAChR agonist PNU protects against nicotine plus HFD-induced hepatic steatosis in obese mice. PNU appears to work at various steps of signaling pathways involving suppression of oxidative stress, activation of AMPK, and inhibition of SREBP1c, FAS, and ACC. a7nAChR agonists may be an effective therapeutic strategy for ameliorating fatty liver disease, especially in obese smokers. (Endocrinology 159: 931-944, 2018) C igarette smoking is the leading preventable cause of death and disability worldwide (1). Smoking is a major risk factor for cardiovascular disease, chronic obstructive pulmonary disease, lung cancer, and nonalcoholic fatty liver disease (NAFLD) (2-6). Importantly, the health risk associated with smoking is further exaggerated by obesity (7, 8 
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Nicotine acts on high-affinity nicotinic acetylcholine receptors (nAChRs), such as a4/b2 receptor, and the lowaffinity receptors such as a7, centrally and peripherally (9) . In rodents, nicotine blocks high-fat diet (HFD)-induced weight gain that was completely blocked by mecamylamine, a nonselective nAChR antagonist, but only partially blocked by the a4/b2 nAChR partial agonist/antagonist varenicline (10) . Nicotine, when given with an HFD, leads to hepatic and muscle steatosis that is thought to be due, at least in part, to increased abdominal fat lipolysis (11) (12) (13) , although the nAChRs involved in this response are not characterized.
Hepatic a3/b4 nAChR has been implicated in chronic nicotine exposure-induced improvement of glycemia and insulin sensitivity (14) . Chronic exposure of nicotine, through the a7-nicotinic acetylcholine receptor (a7nAChR)-mediated pathway, improves glucose homeostasis and insulin sensitivity in genetically obese mice and mice with diet-induced obesity (15) . Treatment with PNU-282987 (PNU), a specific a7nAChR agonist, is also found to be protective against a wide variety of cytotoxic insults and suppresses oxidative stress and apoptosis in various cell systems, including hepatocytes (16) (17) (18) (19) . Indeed, a7nAChRs are present in the liver (14, 16, 20) and the a7nAChR-mediated pathway plays a major role in mitigating hepatic ischemia-reperfusion injury (21, 22) . TC-7020, an a7nAChR agonist, reduced weight gain and improved metabolic disorders in db/db mice (23) .
In the current study, we used PNU and a commonly used model of diet-induced obesity (24) (25) (26) to elucidate the role of a7nAChR agonism in nicotine-induced weight loss and hepatic steatosis in mice on an HFD. Given that oxidative stress and inactivation of adenosine 5 0 -monophosphateactivated protein kinase (AMPK), coupled with hepatocellular apoptosis, play a pivotal role in the pathogenesis of hepatic steatosis (27) (28) (29) , we also examined the effect of a7nAChR agonism on these parameters.
Materials and Methods

Animals
Male C57BL/6 mice weighing 22 to 24 g (Taconic Farms, Germantown, NY) were used in all experiments. Mice were housed under controlled temperature (22 o C) and photoperiod (12-hours light and 12-hours dark cycle) with free access to water and food. Mice were fed either a normal chow diet (NCD) with 5% fat (8.5 KJ/g; laboratory rodent diet #5001, Laboratory Diet, Richmond, IN) or HFD with 60% of calories derived from fat. HFD consisted of 26.2% protein, 26.3% carbohydrate, and 34.9% fat (21.9 KJ/g; D12492, Research Diets, New Brunswick, NJ) for 10 weeks. Groups of five to six mice on either diet received twice daily intraperitoneal (IP) injections of nicotine [0.75 mg/kg body weight (BW)], PNU (0.26 mg/kg BW), PNU plus nicotine (PNU was given 15 minutes before nicotine was administered), or saline for 10 weeks. The rationale for using twice-daily IP administration of nicotine (0.75 mg/kg BW) was based on the results of our previous studies that demonstrated this dose led to levels of nicotine that, when combined with an HFD, triggered greater oxidative stress, activated hepatocellular apoptosis, amplified HFD-induced hepatic steatosis (11, 28) , and caused intramyocellular lipid accumulation and intramyofibrillar mitochondrial abnormalities in the skeletal muscle (13) .
The rationale for using twice-daily IP injections of PNU (0.26 mg/kg BW) was based on the results of a previous study (30) that showed chronic treatment with PNU at the daily dosage of 0.52 mg/kg BW per day) enhanced insulin sensitivity, as judged by reduction in homeostasis model assessment of insulin resistance, glucose tolerance test, and insulin tolerance test, in mice fed an NCD. Additional support for using this dose of PNU was based on the results of our pilot study, which showed that long-term treatment with twice daily IP injections of PNU at this dose was able to prevent nicotine plus HFD-induced hepatic steatosis in male mice (31) .
The rationale for using male C57BL/6 mice is that these male mice, when fed an HFD deriving 60% of calories from fat, develop visceral adiposity, hyperglycemia, insulin and leptin resistance, as well as hepatic steatosis, and are a commonly used model of diet-induced obesity (22) (23) (24) . Moreover, female C57BL6/J mice fed a similar HFD are less sensitive and develop much milder type 2 diabetes than do their male counterparts (32) .
Mice were weighed weekly. The amount of food consumed per mouse was determined daily. Food intake was measured per cage with two to three mice per cage to avoid the stress of individual housing (24) and was calculated per mouse (10) . The cumulative caloric intake was calculated in each group as described previously (10) . Mice were fasted overnight before being euthanized with a lethal injection of sodium pentobarbital (200 mg/kg BW). Livers were removed. Portions of liver were placed in RNAlater and used for gene expression analysis by quantitative real-time polymerase chain reaction (qPCR) or were snap frozen in liquid N 2 and stored frozen for subsequent measurements of triglyceride levels and changes in protein expression by western blotting. The remaining portions of liver were either fixed in 2.5% glutaraldehyde for high-resolution light and electron microscopy or 4% paraformaldehyde for routine histological and immunohistochemical or immunofluorescence studies. Animal handling and experimentation were in accordance with the recommendation of the American Veterinary Medical Association and were approved by the Charles R. Drew University School of Medicine and Science Institutional Animal Care and Use Committee.
Hepatic triglyceride levels
Hepatic triglyceride levels were measured by using Abcam's triglyceride quantitation kit according to manufacturer's protocol (Cambridge, MA).
Assessment of apoptosis
In situ detection of cells with DNA strand breaks was performed in paraformaldehyde-fixed, paraffin-embedded liver sections by the terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP nick end labeling (TUNEL) technique (11, 12, 33) using an ApopTag-peroxidase kit (Chemicon International, San Francisco, CA). Negative and positive controls were carried out for all assays. For negative controls, tissue sections were processed in an identical manner except the TdT enzyme was substituted by the same volume of distilled water. Mammary tissue sections from rat pups 3 to 5 days after weaning (Charles River Laboratories, Worcester, MA) in which apoptosis is well characterized (34) , were used as positive controls. Enumeration of TUNEL-positive nuclei was carried out in liver sections using a microscope with a 340 objective and a pair of 310 eyepieces (Scientific Instruments, Buffalo, NY). Methyl green was used as a counterstain to detect nonapoptotic nuclei. A square grid fitted within one eyepiece provided a reference of 62,500 mm 2 . The rate of hepatocellular apoptosis was expressed as the percentage of the TUNEL-positive apoptotic nuclei per total nuclei (apoptotic plus nonapoptotic) present within the reference area (11, 12, 33) .
Liver pathology
Liver pathology was evaluated using conventional histological analysis on hematoxylin and eosin-stained sections. Additional evaluation of pathology was achieved by highresolution light microscopy using glutaraldehyde-fixed, osmium tetroxide postfixed, epoxy-embedded, and toluidine blue-stained sections and electron microscopy (11, 33) Accumulation of intracellular fat was quantified by computerized densitometry using the ImagePro Plus software coupled to an Olympus BHS microscope equipped with a VCC video camera (11, 33) . For electron microscopic studies, thin sections from selected tissue blocks were sectioned with an LKB ultramichrotome, stained with uranyl acetate, and examined with a Hitachi 600 electron microscope (Hitachi, Indianapolis, IN).
qPCR
Hepatic RNA from mice who were fed an HFD and treated with saline or nicotine in the absence or presence of PNU was extracted with TRIzol Reagent (Invitrogen) using a Pyrex homogenizer. Total RNA was then treated with DNase I (Ambion) for 30 minutes at 37°C and purified with RNeasy mini kit (Qiagen). The purity of RNA was determined by a 260/280 ratio using NanoDrop 2000 (Thermo Fisher Scientific); RNA with .1.9 ratio was considered highly purified. RNA integrity was measured at the University of California, Los Angeles, genomic core using 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA integrity values ranged from 7.5 to 9.2. Complementary DNA (cDNA) was prepared using high-quality RNA to a cDNA kit (Applied Biosystems). cDNA was diluted 1:10, and 3 to 4 mL of the diluted cDNA was used for qPCR. qPCR was done using the
Step One Plus Real-Time PCR System (Life Technologies) with a Sybr Green PCR Master Mix (Applied Biosystems). All reactions were analyzed in triplicate and four to five mice from each group were tested. Data were normalized to 18S ribosomal RNA transcripts using the 2
ΔΔCt method for relative quantitation of gene expression. Primer sequences were as follows:
Western blotting
Western blotting was performed using hepatic lysates as described previously (11, 13, 33) . In brief, proteins (50 to 80 mg) were separated on a 4% to 12% sodium dodecyl sulfate-polyacrylamide gel with 2-(N-morpholine) ethane sulfonic acid buffer (Invitrogen, Carlsbad, CA) at 200V. The gel was transferred onto an immuno-blot polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA) and kept overnight at 4°C. Membranes were blocked in blocking solution (0.3% Tween 20 in Tris-buffered saline and 10% nonfat dry milk) for 1 hour at room temperature, then probed using a mouse monoclonal 4-hydoxynonenal (4-HNE) or rabbit polyclonal silent information regulator 1 (SIRT1), phospho-adenosine-5-monophosphate-activated protein kinase (p-AMPK), total AMPK, phospho-acetyl-COA-carboxylase (p-ACC), and total ACC antibodies (Table 1) for 1 hour at room temperature or overnight at 4°C with constant shaking. Following three 10-minute washes in Tris-buffered saline plus Tween buffer, membranes were then incubated in anti-mouse or anti-rabbit secondary antibody (Jackson ImmunoResearch Laboratories) at a 1:2000 dilution. All antibodies were diluted in blocking buffer. For immunodetection, membranes were washed three times in Tris-buffered saline plus Tween wash buffer, incubated with enhanced chemiluminescence solutions per the manufacturer's specifications (Amersham Biosciences), and exposed to Hyper film enhanced chemiluminescence. Band intensities were determined using Quantity One software from Bio-Rad.
Statistical analysis
Statistical analyses were performed using the SigmaStat 2.0 Program (Jandel, San Rafael, CA). Data are presented as mean 6 standard error of the mean. We used one-way analysis of variance to compare group differences. If overall analysis of variance revealed significant differences, post hoc (pairwise) comparisons were performed using the Tukey or Tukey-Kramer multiple comparison test. Differences were considered significant at P , 0.05.
Results
BW, cumulative food intake, hepatic triglyceride levels, and hepatic steatosis
Nicotine-treated mice fed an HFD had significantly lower BW than did vehicle-treated HFD-fed mice [ Fig. 1(a) ]. By 10 weeks of combined treatment with nicotine and HFD, mean BW was reduced by 27% relative to mice fed with HFD alone. PNU-treated mice fed an HFD also had significantly lower BW than did vehicle-treated mice fed an HFD [ Fig. 1(a) ]. The effect of PNU on BW reduction in HFD-fed mice, however, was less compared with the reduction observed with mice receiving nicotine treatment [ Fig. 1(a) ]. There was no difference in BW between PNU-treated and PNU plus nicotine-treated mice fed an HFD [ Fig. 1 Fig. 1(k) ]. In fact, PNU treatment fully attenuated HFD plus nicotine-induced fat accumulation [ Fig. 1(k) ] to levels seen in mice fed an HFD and saline [ Fig. 1(k) ].
Quantitative image analysis further revealed a substantial increase in intracellular lipid content after combined treatment with HFD and nicotine (215 6 25 mm . We used transmission electron microscopy to further substantiate the light microscopy findings [ Fig. 2(a)-2(h) ]. We next analyzed the occurrence of hepatocellular apoptosis by TUNEL. As demonstrated in Fig. 3(a)-3(g) , HFD alone led to a modest increase in the incidence of apoptosis. Combined with nicotine, the HFD induced a further substantial increase in the incidence of hepatocellular apoptosis. The incidence of hepatocellular apoptosis was similar between the HFD and HFD plus PNU groups. Notably, treatment with PNU significantly attenuated HFD plus nicotine-induced hepatocellular apoptosis to levels similar to that seen in mice given an HFD and saline. There was no staining in liver sections from the nicotine plus HFD group [ Fig. 3(e) ] when TdT enzyme was substituted by the same volume of distilled water (i.e., negative control). In the positive-control mammary tissue sections, an intense immunoreactivity was detected in cells undergoing apoptosis [ Fig. 3(f) ]. Nicotine treatment in the absence or presence of PNU did not alter the incidence of hepatocellular apoptosis in NCD-fed mice (data not shown).
We also used immunoblot analysis to detect a7nAChR expression in the liver [ Fig. 3(h) and 3(i) ]. Hepatic a7nAChR expression was higher in the nicotine and HFD group. PNU treatment effectively prevented nicotine plus HFD-induced increase in a7nAChR expression to levels seen in mice fed an HFD alone. Hepatic expression of a7nAChR was similar in vehicle-treated, PNU-treated, or nicotine plus PNU-treated mice fed an HFD.
PNU prevented nicotine plus HFD-induced hepatic steatosis through stimulation of SIRT1 and APMK signaling together with suppression of oxidative stress AMPK, a central regulator of cellular energy homeostasis, plays an important role in fatty acid metabolism through its ability to regulate key fatty acid biosynthetic pathways (35, 36) . To investigate whether mitigation of nicotine plus HFD-induced hepatic steatosis by PNU was associated with activation of AMPK, we performed western blot analysis of p-AMPK and total AMPK in hepatic lysates [ Fig. 4(a) ]. As expected from our previous studies (11), the HFD, in the absence or presence of nicotine, led to a striking decrease in hepatic p-AMPK levels [ Fig. 4(a) ]. Consistent with the finding of inactivation of AMPK in HFD and HFD plus nicotine-treated groups, little or no p-ACC was detected in hepatic lysates in these groups [ Fig. 4(a) ]. Treatment with PNU significantly attenuated both HFD-and HFD plus nicotine-induced decrease in p-AMPK levels [ Fig. 4(a) ]. PNU alone failed to significantly attenuate HFD-induced decrease in p-ACC levels but restored p-ACC levels in the combined treatment group [ Fig. 4(a) ]. There were no significant differences in total AMPK or total ACC levels among various groups.
Given that SIRT1, a nicotinamide adenine dinucleotidedependent histone deacetylase, plays an important role in protection against hepatic steatosis under various insults (37-39), we next examined the contribution SIRT1 in PNUmediated protection of nicotine plus HFD-induced hepatic steatosis. Western blot analysis revealed that mice fed the HFD in the absence or presence of nicotine exhibited little or no hepatic SIRT1 expression [ Fig. 4(a) ]. Although PNU treatment did not alter HFD-induced decrease in SIRT1 levels, it significantly attenuated nicotine plus HFD-induced decrease in hepatic SIRT1 expression [ Fig. 4(a) ].
Next, we investigated whether amelioration of nicotine plus HFD-induced hepatic steatosis was associated with suppression of oxidative stress. We performed western blot analysis of 4-HNE [ Fig. 4(a) ], a biomarker of oxidative stress (40, 41) . Nicotine-treated mice fed an HFD had significantly higher levels of hepatic 4-HNE relative to mice fed HFD alone. Treatment with PNU significantly attenuated HFD-and HFD plus nicotineinduced increase in hepatic 4-HNE levels. These findings were further corroborated by densitometric analysis of band intensities [ Fig. 4(b) ]. No substantial changes in p-AMPK, SIRT1, or 4-HNE levels were noted among various treatment groups in mice fed the NCD (data not shown).
To gain additional insights into the potential mechanisms of PNU-mediated mitigation of nicotine plus HFD-induced hepatic steatosis, we measured the expression of key genes related to hepatic lipid metabolism by qPCR. Consistent with the finding of inactivation of AMPK in HFD plus nicotine-treated groups, we found substantial upregulation of SREBP1c and fatty acid synthase (FAS) (Fig. 5) , indicating increased hepatic lipogenesis. Treatment with PNU significantly attenuated nicotine plus HFD-induced upregulation of SREBP1c and FAS to levels seen in HFD plus saline or HFD plus PNU groups (Fig. 5) . Consistent with our western blot data, PNU treatment also upregulated hepatic SIRT1 gene expression in nicotine-treated mice fed an HFD. Intriguingly, nicotine treatment resulted in a striking downregulation of CD36 expression in mice fed an HFD. PNU treatment in the absence or presence of nicotine had no effect on nicotine plus HFD-induced changes in CD36 expression. No major changes in the hepatic expression of SCD1 and LXR expression were seen between HFD and HFD plus nicotine-treated groups. Treatment with PNU significantly attenuated both HFD-and HFD plus nicotineinduced upregulation of SCD1 and LXR gene expression (Fig. 5) .
Discussion
In recent studies using the model of diet-induced obesity in C57BL6J mice, we demonstrated that nicotine, when combined with an HFD, triggered greater oxidative stress, activated hepatocellular apoptosis, and exacerbated HFD-induced hepatic steatosis (11, 12 ). In the current study, we evaluated the protective role of PNU, a a7nAChR agonist, on nicotine plus HFD-induced hepatic steatosis. We are intrigued by the observation that, indeed, PNU significantly blocked HFD-induced weight gain and protected nicotine plus HFD-induced hepatic steatosis in obese mice. The preventive effects of PNU on nicotine plus HFD-induced hepatic steatosis are mediated by suppression of oxidative stress and activation of SIRT1 and AMPK signaling, together with inhibition of its downstream targets, including sterol regulatory element binding protein 1c (SREBP1c), ACC, and FAS.
The results of the current study confirm and extend those of our previous studies by demonstrating that nicotine blocks the HFD-induced weight gain in mice (10, 11, 13) . This study is unique, however, in showing that PNU alone can reduce HFD-induced weight gain, albeit less pronounced when compared with nicotine, suggesting an important role of the a7nAChR in the weightreducing effect of nicotine. Indeed, the a7nAChR plays an important role in central and peripheral mechanisms regulating food intake (9) . Consistent with a role of a7nAChR in food intake, we found that PNU treatment alone led to a marked decrease in the cumulative food intake in HFD-fed mice. This notion is supported by another line of evidence showing that TC-7020, an a7nAChR agonist, reduced weight gain and food intake in a mouse model of diabetes (23) . Thus, a potential mechanism by which PNU can reduce BW in HFD-fed mice is through appetite suppression, although this needs to be demonstrated by either showing intracerebroventricular injection of PNU suppresses food intake or that a peripheralacting a7nAChR antagonist such as hexamethonium (42) does not block the effect of a7nAChR agonist on food intake.
Oxidative stress coupled with hepatocyte apoptosis plays a pivotal role in the pathogenesis of NAFLD (27, 29, 43) . Our study showed that nicotine, when combined with an HFD, generated greater oxidative stress, as evidenced by an increase in hepatic 4-HNE levels, than did an HFD alone. Oxidative stress has also been implicated in apoptotic signaling in various cell types, including hepatocytes (27, 29, 44) . Thus, it is likely that generation of severe oxidative stress could trigger hepatocyte apoptosis and aggravate hepatic steatosis in the combined treatment group through the formation of reactive and biologically active lipid peroxidation products such as 4-HNE (27, 29, 43, 45) . This is consistent with our previous data showing that HFD and nicotine can generate oxidative stress in the liver and heart ventricle, but only when they are combined can they cause greater oxidative stress and trigger hepatocyte and cardiomyocyte apoptosis (11, 28) . It is noteworthy that despite a substantial increase in oxidative stress, there was little or no change in the incidence of hepatocyte apoptosis in mice fed an HFD alone, suggesting that the oxidative stress generated by HFD alone is not severe enough to trigger cellular apoptosis. This is consistent with earlier reports indicating that cellular responses to oxidative stress vary depending on the cell type, the levels of stress achieved, and the duration of exposure (46) . However, we cannot rule out the possibility that in addition to high levels of oxidative stress, other factors may have also contributed to increased hepatocyte apoptosis triggered by the combined treatment with nicotine and HFD.
Notably, PNU treatment suppressed nicotine plus HFD-induced increase in hepatic oxidative stress and hepatocellular apoptosis. Indeed, we detected a7nAChR expression in the liver and found the highest amounts of the receptor in the nicotine plus HFD group. This is consistent with previous reports showing that a7nAChRs are present in the liver (14, 16, 20) . PNU treatment significantly prevented nicotine plus HFD-induced increase in a7nAChR expression to levels seen in mice fed an HFD alone. The mechanisms by which PNU prevents nicotine plus HFD-induced increase in a7nAChR expression remain unknown but could be mediated through desensitization of a7nAChR after chronic exposure of the agonist (47) .
Evidence also exists that the a7nAChR-mediated pathway plays a major role in mitigating hepatic ischemiareperfusion injury (21, 22) . Furthermore, the a7nAChR agonist PNU is protective against a wide variety of cytotoxic insults and suppresses oxidative stress and apoptosis in various cell systems, including hepatocytes (16-19, 21, 48, 49) . The underlying mechanisms of the protective effects of PNU in mitigating nicotine plus HFD-induced oxidative stress and hepatocellular apoptosis could include induction of heme oxygenase 1 via nuclear factor erythroid-2-related factor 2 (18, 22, 33) . It also remains possible that PNU can attenuate hepatic steatosis by reducing circulating free fatty acid via reduction of abdominal lipolysis (11) , and improving glucose homeostasis and insulin sensitivity through activation of the a7nAchR-mediated cholinergic antiinflammatory pathway (15) . Other studies have found that chronic treatment of PNU at the same dose levels we used substantially enhanced insulin sensitivity, as judged by reduction in the homeostasis model assessment of insulin resistance, glucose tolerance test, and insulin tolerance test in mice fed an NCD (30) . Available evidence also suggests that PNU administration attenuates the central insulin action-mediated hepatic interleukin-6 and signal transducer and activator of transcription factors 3 in the liver of mice fed an HFD, suggesting that the cholinergic pathway can play an important role in central insulin action-mediated hepatic response in dietinduced obese mice (50) .
One potential limitation of our study is that, at present, we are unable to answer whether PNU would have detrimental effects if used at a 1.5 mg/kg BW per day dosage or if nicotine would have beneficial effects if used at a 0.52 mg/kg BW per day dosage. Indeed, the low dosages (1.5 mg/kg BW per day) of nicotine we used in this study induced adipose tissue lipolysis and hepatic steatosis in mice (11) . In contrast, other studies showed that high dosages of nicotine (4 mg/kg BW per day) improved obesity, hepatic steatosis, and endoplasmic reticulum stress in diet-induced obese male rats (51) . To address the discrepancy between mice and rats, Wu et al. (20) further studied the metabolic effects of both low dosages (0.8 mg/kg BW per day equal to 1.5 mg/kg BW per day in mice) and high dosages of nicotine (4 mg/kg BW per day) in rats. Intriguingly, they found that the low dosage of nicotine, resulting in a serum concentrations of nicotine that is similar to the clinically relevant concentrations found in habitual smokers, induced insulin resistance, mild loss of BW, and hepatic steatosis. In striking contrast, the high dosage of nicotine, resulting in much higher serum nicotine concentrations than found in habitual smokers, induced severe loss of BW, improved insulin sensitivity, and prevented hepatic steatosis in male rats (20) . Although these observations suggest the effects of nicotine could vary depending on dosages, it remains unresolved whether lower doses of nicotine (i.e., ,1.5 mg/kg BW per day) will have detrimental effects on health. Likewise, one could also argue that the beneficial effects of PNU that are so obvious at lower daily dosages (i.e., 0.52 mg/kg BW) ameliorating nicotine plus HFDinduced hepatic steatosis might not be so obvious if used at higher (i.e., 1.5 mg/kg BW) daily dosages. In this context, it is pertinent to note that pretreatment of PNU at a dose of 1 mg/kg BW did protect the liver after ischemia reperfusion injury in mice (19) . Daily dosages of PNU (i.e., 0.3 mg/kg BW and 1.0 mg/kg BW) further inhibited muscular degeneration in mdx dystrophic mice with a greater efficacy at higher dosages (52) . PNU at a slightly higher daily dosage (i.e., 2.4 mg/kg BW) significantly promoted wound healing in a streptozotocininduced diabetic mouse model (53) . Available evidence also suggests that administration of PNU at a much higher dosage (i.e., 12 mg/kg BW) did confer neuroprotection in a mouse model of intracerebral hemorrhage (48) . Thus, given that PNU exerts its beneficial effects at various doses levels in protecting organ damage under diverse experimental conditions, it is unlikely that PNU would have detrimental effects if used at higher daily dosages such as 1.5 mg/kg BW. However, this clearly merits further investigation.
Together, these results demonstrate a key role of the a7nAchR agonist in amelioration of nicotine plus HFDinduced hepatic steatosis. Studies are needed to understand which nAchR(s) is involved in nicotine plus HFD-induced hepatic steatosis and to what extent it is mediated by increased adipose tissue lipolysis, resulting in excess free fatty acid delivery and a direct effect of nicotine in the liver.
AMPK is a central regulator of lipid homeostasis and mediates suppression of lipogenic gene expression such as ACC and FAS through inhibition of SREBP1c (36, 54) . ACC is the rate-determining enzyme for the synthesis malonyl-CoA, a critical substrate for fatty acid biosynthesis and a potent inhibitor of fatty acid oxidation (36) . AMPK can also phosphorylate and inactivate ACC, leading to inhibition of de novo fatty acid and cholesterol synthesis (36) . Consistent with a pivotal role for AMPK in lipid homeostasis, we herein show that the additive effects of nicotine and an HFD on the severity of hepatic steatosis were associated with complete inhibition of AMPK. The net effect of AMPK inactivation was decreased phosphorylation and activation of ACC, leading to increased lipogenesis in the liver. qPCR data also showed a substantial upregulation of SREBP1c and FAS, indicating increased hepatic lipogenesis, in the nicotine plus HFD combined treatment group. These results are consistent with those of our earlier reports (11, 55) and those of others (20, 56) linking inhibition of AMPK with NAFLD. Treatment with PNU restored nicotine plus HFDinduced decrease in hepatic p-AMPK and p-ACC levels and prevented upregulation of SREBP1c and FAS. Furthermore, mice fed HFD for 16 weeks also developed hepatic steatosis in association with inhibition of AMPK coupled with activation of ACC that was attenuated by betaine, a naturally occurring metabolite of choline and an essential biochemical component of the methioninehomocysteine cycle (57) . Taken together, these results indicate that PNU reduced nicotine plus HFD-induced hepatic steatosis by improving AMPK signaling and, in turn, by inactivating ACC and suppressing lipogenic gene expression such as SREBP1c and FAS. At present, we are unable to determine the possible mechanisms by which PNU restores hepatic AMPK activity in nicotinetreated mice fed an HFD and this clearly merits further investigation.
Of further interest, activation of AMPK can also suppress oxidative stress and inhibit apoptosis in various cell systems (58-60). Thus, it is possible that the protective effect of PNU on nicotine plus HFD-induced hepatocyte apoptosis also could be mediated by activation of AMPK. Given the critical role of AMPK in modulating an ever-expanding array of biological pathways, the findings of this study further underscore the potential ability of a7nAChR agonist to mediate a variety of signal transduction pathways in regulating cell fate.
SIRT1 plays an important role in protection against hepatic steatosis under various insults (37) (38) (39) . Consistent with this, we also found that PNU treatment stimulated SIRT1 in the combined treatment group. This is further supported by another line of evidence showing that hepatic overexpression of SIRT1 attenuates hepatic steatosis in mice fed an HFD or after fasting (39), whereas deletion of SIRT1 exacerbates HFD-induced hepatic steatosis (38) .
We found that PNU treatment suppressed HFD plus nicotine-induced upregulation of SCD1 and LXR gene expression in the liver, suggesting that both SCD1 and LXR play an important role in attenuating nicotine plus HFD-induced hepatic steatosis. This is consistent with previous data showing SCD1 deficiency prevented hepatic steatosis observed in several mouse models, including mice fed high-carbohydrate diets and HFD and ob/ob mice (61, 62) . Likewise, downregulation of LXR is involved with suppression of high-cholesterol dietinduced hepatic steatosis though suppression of lipogenic genes such as SREBP1c, SCD1, and FAS (63) . Indeed, we found PNU-mediated amelioration of nicotine plus HFD-induced hepatic steatosis is associated with downregulation of these lipogenic genes.
Nicotine treatment resulted in a striking downregulation of CD36, the fatty acid translocase, in mice fed an HFD. PNU treatment in the absence or presence of nicotine had no effect on nicotine plus HFD-induced decrease in CD36 expression. The upregulation of CD36 in the liver is associated with increased steatosis in patients with NAFLD (64, 65) , and CD36 2/2 mice are resistant to alcohol-and high carbohydrate-induced hepatic steatosis (66) . These observations raise the question of why mice fed an HFD with substantially increased CD36 levels do not develop hepatic steatosis. Alternatively, despite a substantial downregulation of CD36 in the combined treatment, why do these mice develop hepatic steatosis? One possibility is that decreased CD36 expression in the nicotine plus HFD group could reflect a compensatory mechanism aimed at decreasing fatty acid uptake to compensate for HFD-induced increased hepatic lipogenesis. Evidence also exists that hepatic overexpression CD36 attenuates HFD-induced hepatic steatosis (67) . Thus, one could speculate that upregulation of CD36 in the mice fed an HFD might be beneficial in protecting liver under lipid overload and metabolic stress. Thus, the regulation of hepatic lipid homeostasis by CD36 is far more complex and could vary depending on the nature and severity of stress. In summary (Fig. 6 ), we have provided insights into the molecular mechanisms by which PNU attenuates nicotine plus an HFD-induced hepatic steatosis and hepatocellular apoptosis. The preventive effects of PNU on nicotine plus HFD-induced hepatic steatosis appear to be mediated by suppression of oxidative stress, activation of SIRT1 and AMPK signaling, together with inhibition of its downstream targets, including SREBP1c, ACC, and FAS. The clinical implication of this study is that a7nAChR agonists may be an effective therapeutic strategy for the amelioration of NAFLD and adverse metabolic sequelae, especially in obese smokers. Figure 6 . Model illustrating how PNU attenuates nicotine plus HFD-induced hepatic steatosis. Nicotine plus an HFD promotes abdominal lipolysis, resulting in FFA release from adipose tissue into the circulation, thereby contributing to the buildup of lipids as TG in the liver (11) . In addition, nicotine plus an HFD could promote hepatic lipogenesis through inactivation of AMPK and activation of its downstream target ACC, leading to the development of hepatic steatosis. Inactivation of AMPK can also stimulate lipogenesis through upregulation of key genes in the lipogenic pathway such as FAS and ACC by activating the transcription factor sSREBP-1c. Intrahepatic lipid accumulation can also trigger hepatocellular apoptosis through generation of oxidative stress. AMPK inactivation could further sensitize liver cells to nicotine plus HFD-induced apoptosis. PNU seems to protect nicotine plus HFD-induced hepatic steatosis through suppression of oxidative stress and activation of AMPK signaling, together with inhibition of its downstream target, including SREBP1c, ACC, and FAS. FFA, free fatty acid; ROS, reactive oxygen species; TG, triglyceride.
